Bacterial Pneumonia Workup

  • Author: Nader Kamangar, MD, FACP, FCCP, FCCM; Chief Editor: Zab Mosenifar, MD   more...
 
Updated: Jan 3, 2012
 

Approach Considerations

Diagnostic testing in patients with suspected pneumonia is driven mostly by the possibility that the results would significantly alter empiric therapy and management decisions and whether the test is likely to have a high yield.[16, 46] Diagnostic testing is also useful in classifying the severity of illness and site-of-care decisions (outpatient vs inpatient vs intensive care unit [ICU]). The most obvious indication for extensive diagnostic testing is in the critically ill patient.[16, 47]

Various tools to assess the severity of disease and risk of death exist and are in wide use, including the PSI/PORT (ie, pneumonia severity index/Patient Outcomes Research Team score), the CURB-65 system (ie, confusion, urea, respiratory rate, blood pressure, and age >65 y), and the APACHE (ie, acute physiology and chronic health evaluation), among others discussed under Risk Stratification in the Clinical Presentation section. A number of laboratory values are commonly used in the calculation of these risk indices.

Hyponatremia (sodium level < 130 mEq/L) and microhematuria may be associated with Legionella pneumonia. Sputum examination may be supplemented by using a Legionella -specific fluorescent antibody. However, this technique has a high false-negative rate.

Urinary antigen testing for Legionella serogroup 1 organisms is accurate. However, as many as 30% of infections are not caused by serogroup 1 organisms. Pneumococcal antigen tests for serum, urine, and saliva samples have been developed. A Legionella serum antibody titer of 1:128 or more is suggestive of the diagnosis. Antigen-antibody testing has little clinical effect in an emergency department setting, although it may help in recalcitrant or unclear cases.

Imaging studies are generally helpful in detecting suspected pneumonia and identifying the presence of complications; however, only occasionally do radiologic studies suggest specific pathogens.[48]

Next

Routine Laboratory Tests

The following laboratory tests may not be useful for diagnostic purposes but are useful for classifying illness severity and site-of-care/admission decisions[32, 38, 49, 50] (see Risk Stratification under Clinical Presentation):

  • Serum chemistry panel (sodium, potassium, bicarbonate, blood urea nitrogen [BUN], creatinine, glucose)
  • Arterial blood gas (ABG) determination (serum pH, arterial oxygen saturation, arterial oxygen pressure) – Hypoxia and respiratory acidosis may be present.
  • Venous blood gas determination (central venous oxygen saturation)
  • Complete blood cell (CBC) count with differential
  • Serum free cortisol value
  • Serum lactate level

A pulse oximetry finding of < 95% indicates significant hypoxia, and an elevated C-reactive protein (CRP) level may be predictive of more serious disease.[51] However, CRP has not been clearly shown to differentiate bacterial versus viral illness.

Previous
Next

Blood Studies

CBC count with differential

Leukocytosis with a left shift may be observed in any bacterial infection; however, its absence, particularly in patients who are elderly, should not cause the clinician to discount the possibility of a bacterial infection.

Leukopenia (usually defined as a WBC count < 5000 cells/µL) may be an ominous clinical sign of impending sepsis.

Coagulation studies

An elevated international normalized ratio (INR) has been associated with more severe illness. This finding may herald the development of disseminated intravascular coagulation.

Blood cultures

Blood cultures should be obtained before administering antibiotic therapy. These cultures require 24 hours (minimum) to incubate. When the findings are positive, they correlate well with the causative agent.

Unfortunately, blood cultures show poor sensitivity in pneumonia; findings are positive in approximately 40% of cases. Even in pneumococcal pneumonia, the results are often negative. Their yield may be better in patients with more severe cases.

The findings probably have minimal clinical effect in treating bacterial pneumonia. Indeed, the use of blood cultures only rarely dictates a change in antibiotic use.

Previous
Next

Sputum Evaluation

Sputum Gram stain and culture should be performed before initiating antibiotic therapy (if a good-quality, contaminant-sparse specimen containing < 10 squamous epithelial cells per low-power field can be obtained). The white blood cell (WBC) count should be more than 25 per low-power field.

A single predominant microbe should be noted at Gram staining, although mixed flora may be observed with anaerobic infections.

However, often, patients cannot produce an adequate specimen. Many specimens produced are so contaminated by oral materials that they are unusable.

Cultures of the sputum have similar limitations. To be accurate, only specimens that have been examined microscopically and that have satisfied the criteria above should be submitted for culturing.

Previous
Next

Transtracheal Aspiration

In intubated patients admitted to the ICU, some researchers suggest that upper airway samples and cultures obtained initially on admission may aid in directing antibiotic therapy should ventilator-associated pneumonia (VAP) ensue during the first several days of admission.[52]

Fiberoptic bronchoscopy has largely replaced transtracheal aspiration for obtaining lower respiratory secretions.

Previous
Next

Chest Radiography

Chest radiography is considered the criterion standard for diagnosing the presence of pneumonia: The presence of an infiltrate is required for the diagnosis. However, it must be noted that the accuracy of plain chest radiography for detecting pneumonia decreases depending on the setting of infection (see Background).

In H influenzae pneumonia, pleural effusion is present in approximately half of infected individuals.

Go to Imaging Typical Bacterial Pneumonia and Imaging Atypical Bacterial Pneumonia for complete information on these topics.

Lobar pneumonia

Radiographically, lobar pneumonia, or focal or nonsegmental pneumonia, is manifested as nonsegmental, homogeneous consolidation involving one, or less commonly, multiple lobes. Larger bronchi often remain patent with air, creating the characteristic air bronchogram. Lobar consolidation is pathologically the result of the rapid production of edema fluid with minimal cellular reaction, occurring initially in the lung periphery and then spreading between acini through the pores of Kohn and canals of Lambert.

S pneumoniae infection is characterized by homogenous parenchymal lobar opacities with air bronchograms. This condition can occasionally manifest as a round opacity stimulating a pulmonary mass, called round pneumonia. Frank consolidation and air bronchograms have been associated with a higher incidence of bacteremia. The classic findings are in the right lower lobe, but aspiration pneumonia also has a characteristic distribution based on patient positioning.

Aspiration pneumonia radiographic findings may be seen in the gravity-dependent portions of the lungs (affected by patient positioning); the right lung is affected twice as often as the left lung. In recumbent patients, the findings are in the posterior segments of the upper lobes, and, in upright patients, the basal segments of the lower lobes are often affected.

K pneumoniae infection may show radiographic evidence of lobar expansion with bulging of interlobular fissures due to voluminous inflammatory exudate, as well as cavitations. Klebsiella has a tendency to occur in the upper lobes.

Legionella has a predilection for the lower lung fields. Radiologic resolution tends to lag far behind clinical improvement (8 wk to clear).

The following radiographs depict examples of lobar pneumonia.

Bacterial pneumonia. Radiographic images in a patiBacterial pneumonia. Radiographic images in a patient with right upper lobe pneumonia. Note the increased anteroposterior chest diameter, which is suggestive of chronic obstructive pulmonary disease (COPD). Bacterial pneumonia. Radiographic images in a patiBacterial pneumonia. Radiographic images in a patient with bilateral lower lobe pneumonia. Note the spine sign, or loss of progression of radiolucency of the vertebral bodies Bacterial pneumonia. Radiographic images in a patiBacterial pneumonia. Radiographic images in a patient with early right middle lobe pneumonia.

Bronchopneumonia

Bronchopneumonia, also known as multifocal or lobular pneumonia, is radiographically identified by its patchy appearance, with peribronchial thickening and poorly defined air-space opacities. As illness becomes more severe, consolidation involving the terminal and respiratory bronchioles and alveoli results in the development of centrilobular nodular opacities or air-space nodules; this consolidation can develop further and coalesce to give a lobular or lobar pattern of involvement.

Typically, air bronchograms are absent. The pathogens known to cause this pattern of pneumonia are particularly destructive; thus, abscesses, pneumatoceles, and pulmonary gangrene are often seen. Pathologically, bronchopneumonia stems from inflammation of large airways (bronchitis) with patchy (lobular) involvement.

In S aureus pneumonia, lobar enlargement with bulging of interlobular fissures can be seen in severe cases. Abscesses, cavitations (with air-fluid levels), and pneumatoceles are commonly seen, and 30-50% of patients develop pleural effusions, half of which are empyemas. Note that cavitation and associated pleural effusions are also observed in cases of anaerobic infections, gram-negative infections, and tuberculosis.

In P aeruginosa infection, the radiographic findings tend to be nonspecific and difficult to differentiate from underlying lung disease. Usually all the lobes are involved, with a predilection for the lower lobes, and necrosis and cavitation occur frequently. In addition, pulmonary vasculitis can produce areas of pulmonary infarction that radiographically resembles invasive aspergillosis.

Interstitial pneumonia

Interstitial pneumonia is classified as focal or diffuse. Pathologically, the radiographic pattern results from edema and inflammatory cellular infiltrate into the interstitial tissue of the lung. The pathologic development of interstitial pneumonia generally takes 1 of 2 forms: (1) an insidious infectious course that results in lymphatic infiltration of alveolar septa without parenchymal abnormality or (2) acute or rapidly progressive disease that results in diffuse alveolar damage affecting the interstitial and air spaces. Radiographically, the disease manifests with a reticular or reticulonodular pattern.[53, 54]

Previous
Next

Chest CT Scanning

The role of computed tomography (CT) scanning in the diagnosis of pneumonia is not yet well defined. For inpatients, CT scanning may identify pulmonary infections earlier than plain radiography.[47] In most cases, it can be helpful in the analysis of more complex lung findings and the evaluation of other intrathoracic structures. In unclear cases, high-resolution CT scanning of the lungs may aid in the diagnosis.

CT patterns of disease may be broken down into abnormalities that cause either increased or decreased lung opacity.[55] Abnormalities that cause increased lung opacity include the following:

  • Nodular pattern, based on the anatomy of the secondary pulmonary lobule – A centrilobular pattern is further characterized by the presence or absence of tree-in-bud morphology, the presence of which is almost always seen in infection; its absence is likely to expand the differential beyond infectious processes. Other nodules include perilymphatic nodules and random nodules.
  • Linear patter - Interlobular septal thickening (smooth, nodular, irregular), parenchymal bands, subpleural lines, and irregular linear opacities may be seen.
  • Reticular pattern
  • Ground-glass opacity
  • Consolidation

Abnormalities that cause decreased lung opacity include the following:

  • Bronchiectasis
  • Emphysematous change (centrilobular, panlobular, paraseptal, irregular)
  • Honeycomb lung and cystic disease
  • Mosaic perfusion and inhomogeneous lung opacity

Go to Imaging Typical Bacterial Pneumonia and Imaging Atypical Bacterial Pneumonia for complete information on these topics.

Previous
Next

Chest Ultrasonography

Ultrasonography is useful in evaluating suspected parapneumonic effusions, especially if septations are present within the fluid collection that may not be visible on CT scans. Ultrasonography also has great utility for direct operation by physicians at the patient bedside.[48]

Previous
Next

Bronchoscopy With or Without BAL

Lung tissue can be visually evaluated and bronchial washing specimens can be obtained with the aid of a fiberoptic bronchoscope. Protected brushings and bronchoalveolar lavage (BAL) can be performed for fluid analysis and cultures.

BAL can also be performed without the use of a bronchoscope.

Previous
Next

Thoracentesis

This is an essential procedure in patients with a parapneumonic pleural effusion. Obtaining fluid from the pleural space for laboratory analysis allows for the differentiation between simple and complicated effusions. This determination may help guide further therapeutic intervention.

Pleural effusions and frank empyema fluid should also be sent for Gram stain and culture.

Previous
Next

Other Pathogen-Specific Tests

  • Urine assays also available for the rapid detection of Legionella and pneumococcal antigens. These fast card-type assays have been developed in recent years, may be performed at the bedside, and may be useful in unclear cases or when the choices for antimicrobial therapy are limited.
  • Sputum and/or urinary antigen tests are available for Legionella pneumophila.
  • Sputum, serum, and/or urinary antigen tests are available for Streptococcus pneumoniae.
  • Immune serologic tests have been developed for Mycoplasma pneumoniae, Chlamydophila pneumoniae, L pneumophila, and Coxiella burnetii. However, the results are usually not available until several weeks after the infection, which makes these tests less useful.
  • Nucleic acid detection (eg, polymerase chain reaction [PCR]) is still in development, but this test poses a major weakness in its extreme sensitivity and potential for false-positive results, also rendering it less useful than other tests.
Previous
Next

Histology

Histologic inflammatory lung changes are best described according to the pattern of infection.[56]

Lobar pneumonia

Four stages of inflammatory response are classically described, as follows:

  1. Congestion: This stage is characterized by vascular engorgement, intraalveolar fluid, and numerous bacteria. The lung is heavy, boggy, and red.
  2. Red hepatization: In this stage, massive confluent exudation develops, with red blood cells, leukocytes, and fibrin filling the alveolar spaces. The affected area appears red, firm, and airless, with a liverlike consistency.
  3. Gray hepatization: This stage is characterized by progressive disintegration of red blood cells and the persistence of a fibrin exudate.
  4. Resolution: The consolidated exudate within the alveolar spaces undergoes progressive enzymatic digestion to produce debris that is later resorbed, ingested by macrophages, coughed up, or becomes organized by fibroblasts growing into it.

Bronchopneumonia

Bronchopneumonia typically consists of foci of consolidation resulting from a suppurative, leukocyte-rich exudate that fills the bronchi, bronchioles, and adjacent alveolar spaces. In terms of gross appearance, well-developed lesions may be 3-4 cm in diameter, dry, granular, and grayish-red to yellow, with poorly demarcated margins.

Interstitial pneumonia

The typical lung inflammatory response to the atypical bacteria results in an interstitial picture. Alveolar septa become widened and edematous and usually have a mononuclear inflammatory infiltrate of lymphocytes, histiocytes, and plasma cells. Neutrophils may also be present in acute cases. Pleuritis may result if the underlying inflammation extends to the pleural surface of the lung.

Previous
 
 
Contributor Information and Disclosures
Author

Nader Kamangar, MD, FACP, FCCP, FCCM  Associate Professor of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Los Angeles, David Geffen School of Medicine, Olive View-UCLA Medical Center; Associate Program Director, Pulmonary and Critical Care Multi-Campus Fellowship Program, Cedars-Sinai/West Los Angeles Veterans Affairs/Los Angeles Kaiser Permanente/Olive View-UCLA Medical Center; Site Director, Pulmonary/Critical Care Fellowship Program, Olive View-UCLA Medical Center

Nader Kamangar, MD, FACP, FCCP, FCCM is a member of the following medical societies: American Academy of Sleep Medicine, American Association of Bronchology, American College of Chest Physicians, American College of Physicians, American Lung Association, American Medical Association, American Thoracic Society, California Thoracic Society, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Annie Harrington, MD  Fellow in Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center

Annie Harrington, MD is a member of the following medical societies: Alpha Omega Alpha and American College of Chest Physicians

Disclosure: Nothing to disclose.

Christina Rager, MD  Resident Physician, Internal and Emergency Medicine, Olive View-University of California at Los Angeles Medical Center

Christina Rager, MD is a member of the following medical societies: American College of Physicians, American Medical Student Association/Foundation, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Dana A Stearns, MD  Assistant Director of Undergraduate Education, Department of Emergency Medicine, Massachusetts General Hospital

Dana A Stearns, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

James M Stephen, MD, FAAEM, FACEP  Assistant Professor, Tufts University School of Medicine; Attending Physician, Director of Medical Informatics and Graduate Education, Department of Emergency Medicine, Tufts Medical Center

James M Stephen, MD, FAAEM, FACEP is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

Ryland P Byrd Jr, MD  Professor, Department of Internal Medicine, Division of Pulmonary Medicine and Critical Care Medicine, Program Director of Pulmonary Diseases and Critical Care Medicine Fellowship, East Tennessee State University, James H Quillen College of Medicine; Medical Director of Respiratory Therapy, James H Quillen Veterans Affairs Medical Center

Ryland P Byrd Jr, MD is a member of the following medical societies: American College of Chest Physicians and American Thoracic Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Paul Blackburn, DO, FACOEP, FACEP  Attending Physician, Department of Emergency Medicine, Maricopa Medical Center

Paul Blackburn, DO, FACOEP, FACEP is a member of the following medical societies: American College of Emergency Physicians, American College of Osteopathic Emergency Physicians, American Medical Association, and Arizona Medical Association

Disclosure: Nothing to disclose.

Barry E Brenner, MD, PhD, FACEP  Professor of Emergency Medicine, Professor of Internal Medicine, Program Director, Emergency Medicine, Case Medical Center, University Hospitals, Case Western Reserve University School of Medicine

Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy of Sciences, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Zab Mosenifar, MD  Director, Division of Pulmonary and Critical Care Medicine, Director, Women's Guild Pulmonary Disease Institute, Professor and Executive Vice Chair, Department of Medicine, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine

Zab Mosenifar, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, and American Thoracic Society

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors Sat Sharma, MD, FRCPC,to the development and writing of a source article.

References
  1. Stedman's Medical Dictionary. 27th ed. Baltimore, Md: Lippincott, Williams and Wilkins; 2003.

  2. Brundage JF, Shanks GD. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis. Aug 2008;14(8):1193-9. [Medline]. [Full Text].

  3. Anand N, Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med. Feb 2009;30(1):3-9. [Medline].

  4. El Solh AA. Nursing home-acquired pneumonia. Semin Respir Crit Care Med. Feb 2009;30(1):16-25. [Medline].

  5. Kuti JL, Shore E, Palter M, Nicolau DP. Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines. Semin Respir Crit Care Med. Feb 2009;30(1):102-15. [Medline].

  6. Eggimann P, Pittet D. Infection control in the ICU. Chest. Dec 2001;120(6):2059-93. [Medline].

  7. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. Sep 15 2005;41(6):848-54. [Medline].

  8. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. May 13 2010;362(19):1804-13. [Medline].

  9. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. Mar 1 2001;344(9):665-71. [Medline].

  10. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med. Feb 14 2008;358(7):716-27. [Medline]. [Full Text].

  11. Rubins JB, Janoff EN. Pneumolysin: a multifunctional pneumococcal virulence factor. J Lab Clin Med. Jan 1998;131(1):21-7. [Medline].

  12. Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. Jun 1 2005;171(11):1209-23. [Medline]. [Full Text].

  13. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. Jul 2006;19(3):571-82. [Medline]. [Full Text].

  14. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. Oct 1 2008;198(7):962-70. [Medline]. [Full Text].

  15. Forgie S, Marrie TJ. Healthcare-associated atypical pneumonia. Semin Respir Crit Care Med. Feb 2009;30(1):67-85. [Medline].

  16. [Guideline] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. Mar 1 2007;44 Suppl 2:S27-72. [Medline].

  17. Centers for Disease Control and Prevention. Pneumonia. Available at http://www.cdc.gov/Features/Pneumonia/. Accessed January 13, 2011.

  18. Restrepo MI, Anzueto A. The role of gram-negative bacteria in healthcare-associated pneumonia. Semin Respir Crit Care Med. Feb 2009;30(1):61-6. [Medline].

  19. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep. Oct 2 2009;58(38):1071-4. [Medline].

  20. 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care - New York City, 2009. MMWR Morb Mortal Wkly Rep. Mar 26 2010;59(11):321-6. [Medline].

  21. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Tularemia as a biological weapon: medical and public health management. JAMA. Jun 6 2001;285(21):2763-73. [Medline].

  22. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. Dec 2002;122(6):2115-21. [Medline].

  23. American Lung Association. Trends in pneumonia and influenza morbidity and mortality. September 2008. American Lung Association. Available at http://bit.ly/gwYJAE. Accessed January 13, 2011.

  24. Kung HC, Hoyert DL, Xu JQ, Murphy SL, and the Division of Vital Statistics. Deaths: final data for 2005. National Vital Statistics Reports. Hyattsville, Md: National Center for Health Statistics April 2008: 56(10). http://www.cdc.gov. Available at http://bit.ly/i3ATH5. Accessed January 13, 2011.

  25. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med. Jul 26 1999;107(1A):34S-43S. [Medline].

  26. Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. Apr 2011;66(4):340-6. [Medline].

  27. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. Oct 31 2009;374(9700):1543-56. [Medline].

  28. Slovis BS, Brigham KL. Cecil Essentials of Medicine. In: : Andreoli T, Carpenter CCJ, Griggs RC, Loscalzo J. Approach to the patient with respiratory disease. 6th ed. WB Saunders Co: Philadelphia, Pa; 2004:177-80.

  29. Claudius I, Baraff LJ. Pediatric emergencies associated with fever. Emerg Med Clin North Am. Feb 2010;28(1):67-84, vii-viii. [Medline].

  30. Brown SM, Jones BE, Jephson AR, Dean NC. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med. Dec 2009;37(12):3010-6. [Medline]. [Full Text].

  31. Fang WF, Yang KY, Wu CL, Yu CJ, Chen CW, Tu CY, et al. Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia. Crit Care. Jan 19 2011;15(1):R32. [Medline].

  32. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. May 2003;58(5):377-82. [Medline]. [Full Text].

  33. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. Jan 23 1997;336(4):243-50. [Medline].

  34. Agency for Healthcare Research and Quality. Pneumonia severity index calculator. Available at http://pda.ahrq.gov/clinic/psi/psicalc.asp. Accessed January 13, 2011.

  35. Sligl WI, Majumdar SR, Marrie TJ. Triaging severe pneumonia: what is the "score" on prediction rules?. Crit Care Med. Dec 2009;37(12):3166-8. [Medline].

  36. Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax. Jul 2009;64(7):598-603. [Medline].

  37. Bloos F, Marshall JC, Dellinger RP, et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care. Mar 7 2011;15(2):R88. [Medline].

  38. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. Oct 1985;13(10):818-29. [Medline].

  39. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. Dec 22-29 1993;270(24):2957-63. [Medline].

  40. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. Jul 1996;22(7):707-10. [Medline].

  41. El-Solh AA, Alhajhusain A, Abou Jaoude P, Drinka P. Validity of severity scores in hospitalized patients with nursing home-acquired pneumonia. Chest. Dec 2010;138(6):1371-6. [Medline].

  42. España PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. Dec 1 2006;174(11):1249-56. [Medline].

  43. Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. Feb 2009;37(2):456-62. [Medline].

  44. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. Aug 1 2008;47(3):375-84. [Medline].

  45. Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, et al. Procalcitonin and C reactive protein in hospitalised adult patients with community acquired pneumonia, exacerbation of asthma and chronic obstructive pulmonary disease. Chest. Oct 28 2010;[Medline].

  46. Skerrett SJ. Diagnostic testing for community-acquired pneumonia. Clin Chest Med. Sep 1999;20(3):531-48. [Medline].

  47. Smith PR. What diagnostic tests are needed for community-acquired pneumonia?. Med Clin North Am. Nov 2001;85(6):1381-96. [Medline].

  48. Ketai L, Jordan K, Marom EM. Imaging infection. Clin Chest Med. Mar 2008;29(1):77-105, vi. [Medline].

  49. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. Feb 20 2003;348(8):727-34. [Medline].

  50. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. Nov 8 2001;345(19):1368-77. [Medline].

  51. Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med. Dec 2009;24(4):337-42. [Medline]. [Full Text].

  52. Pirracchio R, Mateo J, Raskine L, Rigon MR, Lukaszewicz AC, Mebazaa A, et al. Can bacteriological upper airway samples obtained at intensive care unit admission guide empiric antibiotherapy for ventilator-associated pneumonia?. Crit Care Med. Sep 2009;37(9):2559-63. [Medline].

  53. Gharib AM, Stern EJ. Radiology of pneumonia. Med Clin North Am. Nov 2001;85(6):1461-91, x. [Medline].

  54. Tarver RD, Teague SD, Heitkamp DE, Conces DJ Jr. Radiology of community-acquired pneumonia. Radiol Clin North Am. May 2005;43(3):497-512, viii. [Medline].

  55. Gotway MB, Reddy GP, Webb WR, Elicker BM, Leung JW. High-resolution CT of the lung: patterns of disease and differential diagnoses. Radiol Clin North Am. May 2005;43(3):513-42, viii. [Medline].

  56. Hussain AN, Kumar V. The lung. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran: Pathologic Basis of Disease. 7th ed. Philadelphia, Pa: Elsevier Saunders; 2005:711-72.

  57. [Guideline] Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. Jan 2008;34(1):17-60. [Medline]. [Full Text].

  58. Arnold FW, LaJoie AS, Brock GN, Peyrani P, Rello J, Menéndez R, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med. Sep 14 2009;169(16):1515-24. [Medline].

  59. McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med. Sep 14 2009;169(16):1525-31. [Medline].

  60. [Guideline] Centers for Medicare and Medicaid Services, Joint Commission. Specifications manual for national hospital inpatient quality measures. V. 2.6b. Manual download retrieved April 2009.

  61. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med. Sep 2010;38(9):1802-8. [Medline].

  62. Lam AP, Wunderink RG. The role of MRSA in healthcare-associated pneumonia. Semin Respir Crit Care Med. Feb 2009;30(1):52-60. [Medline].

  63. Centers for Disease Control and Prevention. H1N1 Flu: Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States April 2009 - April 10, 2010. Available at http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm. Accessed June 1, 2010.

  64. Sullivan SJ, Jacobson RM, Dowdle WR, Poland GA. 2009 H1N1 influenza. Mayo Clin Proc. Jan 2010;85(1):64-76. [Medline]. [Full Text].

  65. Tang KL, Eurich DT, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med. Jul 11 2011;171(13):1193-8. [Medline].

  66. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. May 1 2010;181(9):975-82. [Medline].

  67. FDA requests boxed warnings on fluoroquinolone antimicrobial drugs: seeks to strengthen warnings concerning increased risk of tendinitis and tendon rupture [press release]. Silver Spring, Md: US Food and Drug Administration; July 8, 2008. FDA. Available at http://bit.ly/fkBFeA. Accessed January 14, 2011.

  68. US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox®) is given to patients taking certain psychiatric medications. Available at http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm. Accessed July 27, 2011.

  69. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS. The Sanford Guide to Antimicrobial Therapy: 2010. 40th ed. Sperryville, Va: Antimicrobial Therapy, Inc; 2009.

Previous
Next
 
Bacterial pneumonia. Radiographic images in a patient with right upper lobe pneumonia. Note the increased anteroposterior chest diameter, which is suggestive of chronic obstructive pulmonary disease (COPD).
Bacterial pneumonia. Radiographic images in a patient with bilateral lower lobe pneumonia. Note the spine sign, or loss of progression of radiolucency of the vertebral bodies
Bacterial pneumonia. Radiographic images in a patient with early right middle lobe pneumonia.
Table. Pathogen-Driven Antibiotic Choices[16]
OrganismFirst-Line AntimicrobialsAlternative Antimicrobials
Streptococcus pneumoniae
Penicillin susceptible



(MIC < 2 mcg/mL)



Penicillin G, amoxicillinMacrolide, cephalosporin (oral or parenteral), clindamycin, doxycycline, respiratory fluoroquinolone
Penicillin resistant



(MIC ≥2 mcg/mL)



Agents chosen on the basis of sensitivityVancomycin, linezolid, high-dose amoxicillin (3 g/d with MIC ≤4 mcg/mL
Staphylococcus aureus
Methicillin susceptibleAntistaphylococcal penicillinCefazolin, clindamycin
Methicillin resistantVancomycin, linezolidTrimethoprim- sulfamethoxazole
Haemophilus influenzae
Non–beta-lactamase producingAmoxicillinFluoroquinolone, doxycycline, azithromycin, clarithromycin
Beta-lactamase producingSecond- or third-generation cephalosporin, amoxicillin/clavulanateFluoroquinolone, doxycycline, azithromycin, clarithromycin
Mycoplasma pneumoniaeMacrolide, tetracyclineFluoroquinolone
Chlamydophila pneumoniaeMacrolide, tetracyclineFluoroquinolone
Legionella speciesFluoroquinolone, azithromycinDoxycycline
Chlamydophila psittaciTetracyclineMacrolide
Coxiella burnetiiTetracyclineMacrolide
Francisella tularensisDoxycyclineGentamicin, streptomycin
Yersinia pestisStreptomycin, gentamicinDoxycycline, fluoroquinolone
Bacillus anthracis (inhalational)Ciprofloxacin, levofloxacin, doxycyclineOther fluoroquinolones, beta-lactam (if susceptible), rifampin, clindamycin, chloramphenicol
EnterobacteriaceaeThird-generation cephalosporin, carbapenemBeta-lactam/beta-lactamase inhibitor, fluoroquinolone
Pseudomonas aeruginosaAntipseudomonal beta-lactam plus ciprofloxacin, levofloxacin, or aminoglycosideAminoglycoside plus ciprofloxacin or levofloxacin
Bordetella pertussisMacrolideTrimethoprim- sulfamethoxazole
Anaerobe (aspiration)Beta-lactam/beta-lactamase inhibitor, clindamycinCarbapenem
MIC = Minimal inhibitory concentration.
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.